Exchange Traded Concepts LLC Has $6.85 Million Stock Position in Abbott Laboratories $ABT

Key Points

• Exchange Traded Concepts LLC increased its Abbott Laboratories stake by 31.7% in the second quarter, bringing its holdings to 75,528 shares valued at approximately $6.85 million. Institutional investors collectively own 75.18% of Abbott’s stock.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $118.67. Abbott recently exceeded quarterly earnings and revenue expectations, reporting $1.31 in EPS and $12.59 billion in revenue, while raising its presence in diabetes care and diagnostics.
• Abbott pays a quarterly dividend of $0.63 per share, equivalent to a 2.2% yield, but faces notable legal risks. The company agreed to a roughly $670 million settlement tied to infant-formula litigation and separately settled an appeal involving a $495 million verdict.

Exchange Traded Concepts LLC increased its stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 31.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 75,528 shares of the healthcare product maker's stock after purchasing an additional 18,196 shares during the period. Exchange Traded Concepts LLC's holdings in Abbott Laboratories were worth $6,853,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Pines Wealth Management LLC grew its position in shares of Abbott Laboratories by 6.5% during the 2nd quarter. Pines Wealth Management LLC now owns 4,829 shares of the healthcare product maker's stock worth $438,000 after buying an additional 296 shares during the period. Citizens National Bank Trust Department boosted its stake in Abbott Laboratories by 77.3% during the 2nd quarter. Citizens National Bank Trust Department now owns 25,885 shares of the healthcare product maker's stock worth $2,349,000 after acquiring an additional 11,285 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in Abbott Laboratories by 38.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,895,185 shares of the healthcare product maker's stock valued at $171,969,000 after purchasing an additional 522,279 shares during the period. E Fund Management Hong Kong Co. Ltd. increased its stake in Abbott Laboratories by 221.6% in the second quarter. E Fund Management Hong Kong Co. Ltd. now owns 476 shares of the healthcare product maker's stock valued at $43,000 after purchasing an additional 328 shares in the last quarter. Finally, Sumitomo Mitsui DS Asset Management Company Ltd boosted its position in shares of Abbott Laboratories by 1.0% during the second quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 249,455 shares of the healthcare product maker's stock worth $22,636,000 after purchasing an additional 2,385 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on ABT. Robert W. Baird initiated coverage on shares of Abbott Laboratories in a report on Wednesday, July 1st. They issued an "outperform" rating and a $121.00 price target for the company. The Goldman Sachs Group reduced their target price on Abbott Laboratories from $121.00 to $113.00 and set a "buy" rating on the stock in a report on Wednesday, May 27th. TD Cowen restated a "buy" rating and issued a $115.00 price target on shares of Abbott Laboratories in a report on Friday, July 17th. Bank of America cut their price objective on Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. Finally, UBS Group decreased their price objective on Abbott Laboratories from $135.00 to $125.00 and set a "buy" rating for the company in a research report on Tuesday, July 28th. Three analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $118.67.

Abbott Laboratories Stock Performance

Shares of ABT opened at $114.16 on Friday. The stock has a market capitalization of $197.54 billion, a price-to-earnings ratio of 36.94, a PEG ratio of 2.21 and a beta of 0.59. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49. The firm has a fifty day simple moving average of $99.51 and a 200 day simple moving average of $99.93. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm had revenue of $12.59 billion for the quarter, compared to analysts' expectations of $12.52 billion. During the same period in the previous year, the firm posted $1.26 EPS. The company's revenue for the quarter was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Research analysts forecast that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 2.2%. The ex-dividend date was Wednesday, July 15th. Abbott Laboratories's dividend payout ratio is presently 81.55%.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott’s Instinct continuous glucose sensor is now integrated into MiniMed’s Flex automated insulin-delivery system, which is commercially shipping in the United States. The partnership expands Abbott’s presence in the growing continuous glucose-monitoring and diabetes-care markets. MiniMed Ships MiniMed Flex With Abbott’s Smallest Instinct Sensor
• Positive Sentiment: Abbott entered a multiyear agreement with HealthTab to supply Afinion 2 analyzers for point-of-care HbA1c and lipid testing in UK pharmacies, supporting the Diagnostics segment and potential NHS-linked distribution. HealthTab Enters Multi-Year Collaboration Agreement with Abbott
• Positive Sentiment: Analyst commentary continues to identify electrophysiology, continuous glucose-monitoring adoption and Abbott’s cardiovascular pipeline as important long-term growth drivers for the Medical Devices business. Abbott’s Medical Devices Growth Catalyst
• Neutral Sentiment: Recent commentary remains broadly constructive on Abbott’s long-term outlook, although one analysis characterized the stock as reasonably valued after its recent advance while another recommended a more cautious stance. This suggests valuation could limit near-term upside despite favorable operating trends.
• Negative Sentiment: Abbott agreed to pay approximately $670 million to resolve the Gill case and claims involving about 2,000 individuals concerning specialty formulas for premature infants. Although the company maintains that the products are safe and denies reliable evidence linking them to necrotizing enterocolitis, the settlement creates a substantial financial cost and keeps litigation risk in focus. Abbott Agrees to $670 Million Settlement
• Negative Sentiment: The company also settled an appeal related to a separate $495 million infant-formula verdict, reinforcing investor concerns about potential legal expenses and liabilities in the Nutrition business. Abbott Settles Appeal Over $495 Million Infant Formula Verdict

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source